- Our LinkedIn Page
- Our Twitter Feed
- Our Facebook Page
- Newsletter Subscribe to our e-newsletter. Current Issue
- Our Flickr Feed
- Our YouTube Feed
Tags
Health Care One-on-One's BIO International Convention biofuels biotech industry climate change agriculture Biotechnology Industry biofuel Industry Analysis Sustainability biotechnology patent Biofuel Technology Technology Transfer Partnering Plant biotechnology Food global food crisis Benefits of biotech cropsAuthors
- Abigail Hirsch
- Alan Eisenberg
- BIOtechNOW Editor
- Bruce Dale
- Celia Economides
- Colleen Lerro
- David Thomas, CFA
- George Goodno
- George MacDougall
- Jason Corum
- Jeff Joseph
- Jim Greenwood
- Karen Batra
- Kelly Cappio
- Lila Feisee
- Matt Carr
- Nathan Schock
- Paul Winters
- Paulina Ibarra
- Robbi Lycett
- Roy Zwahlen
- Sarah Sneeringer
- Sondra Behan
- Stephanie Fischer
- Stephen Marmaras
- Tracy Cooley
Author Archive: Jason Corum
Jason is the web editor with the Biotechnology Industry Organization (BIO). Prior to joining BIO in March 2011, he was the online communications manager for World Food Program USA and an online communications specialist with the Brookings Institution.
Jason is originally from Evergreen Park, Ill. and still thinks that Chicago is the best food city in the nation. He spends his free time volunteering with the DC Books to Prisons Project, watching movies and following Ozzie Guillen on Twitter.Latest Posts
Picks and Pans – The Buy-Side View for 2012
What’s the forecast for biotech in 2012? Do investors think it is a good time to invest in biotechnology? Are they interested in taking on early stage companies? At the BIO CEO & Investor Conference opening plenary, the BIO Industry Analysis team released results from their Investor Perception Study and, afterwards, a panel of portfolio managers and senior buy-side analysts fielded a range of question about the challenges and opportunities facing the industry. David Gluckman, M.D., Read More >
“Alz” Well That Ends Well: The Beta-Amyloid Debate in Alzheimer’s Research
Researchers and clinicians alike believe there is substantial evidence to support the hypothesis that Alzheimer’s disease (AD) may be caused by deposition of amyloid beta-peptide (Abeta) in plaques in brain tissue. But drugs targeted towards the beta-amyloid have met with significant setbacks challenging whether the target is, in fact, real. With several late stage drugs targeting beta-amyloid poised for market entry, a panel of opinion leaders in the treatment of Alzheimer’s and scientific industry specialists Read More >
Fireside Chat with Moncef Slaoui, GlaxoSmithKline
Moncel Slaoui, chairman of research and development (R&D) at GlaxoSmithKline (GSK), opened the 2012 BIO CEO & Investor Conference with a Fireside Chat where he provided insight in to his company’s biopharma R&D strategy. “GSK has announced that our R&D budget is no more a percentage of sales. If you think about it, it doesn’t make sense,” Slaoui stated, “because, sales are a marker of R&D 10 and 15 years ago.” Right now, GSK has Read More >
NIH: Streamlining the Technology Transfer Process
The National Institutes of Health (NIH) is launching the electronic Research Materials catalogue (eRMa) to streamline the federal government’s technology transfer process. “To stay competitive in today’s world, on-line ordering is a requirement. With the launch of this first-of-its kind system, OTT is demonstrating its intention to meet that challenge,” said Mark Rohrbaugh, director of OTT. According to the press release: “The new system will streamline the licensing process by: Providing a website for companies Read More >
Developing Cancer Therapies and Diagnostics: 4 Pieces of Advice
Insights in to the molecular and genetic basis of disease are driving new product and therapeutic opportunities while changing the treatment paradigm for many cancers. The use of companion diagnostics in oncology may play a role in optimizing and expediting the development of targeted therapies for many cancers and other conditions. Focusing on these new markets, a panel of industry executives and investors at the 2011 BIO Investor Forum discussed some of the most compelling Read More >
